tiprankstipranks
Trending News
More News >
IMCD N.V. (NL:IMCD)
:IMCD
Advertisement

IMCD N.V. (IMCD) AI Stock Analysis

Compare
4 Followers

Top Page

NL:IMCD

IMCD N.V.

(LSE:IMCD)

Rating:63Neutral
Price Target:
€104.00
▲(9.13% Upside)
The stock's overall score is primarily influenced by financial performance, which highlights strong revenue growth but raises concerns over leverage and cash flow. Technical analysis suggests bearish market trends, while valuation indicates potential overvaluation despite a reasonable dividend yield.

IMCD N.V. (IMCD) vs. iShares MSCI Netherlands ETF (EWN)

IMCD N.V. Business Overview & Revenue Model

Company DescriptionIMCD N.V. distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. The company offers enzymes, surfactants, biocides, chelates, rheology modifiers, solubilisers, silicones, solvents, and functional additives; active pharmaceutical, agrochemicals, biopharma, excipients and formulation, nutraceuticals, and regulated synthesis; actives, UV sunscreens, rheology modifiers, thickeners, emulsifiers, emollients, elastomers, humectants, waxes, film formers, functional powders, hair styling polymers, hair conditioners, solvents, solubilizers, pigments, pearls, colorants, opacifiers, pearlisers, preservatives, antioxidants, additives, fragrances, and essential oils; and resins and binders, additives, functional fillers, and specialty solvents. It also provides taste, texture, nutrition, and function; base oil, fuel addictive, lubricants addictive, lubricants finished fluids, solvents, degreasers and fuel, compounds, and upstream, midstream and downstream oil, gas and energy; bio-based chemicals, catalysts, intermediates, monomers, organic building blocks, processing aids, reactive diluents, solvents, and surfactants. IMCD N.V. was founded in 1995 and is headquartered in Rotterdam, the Netherlands.
How the Company Makes MoneyIMCD generates revenue primarily through the distribution of specialty chemicals and food ingredients. The company operates on a model that involves purchasing products from manufacturers and selling them to customers, earning a margin on each transaction. Key revenue streams include sales of chemicals across various sectors, such as pharmaceuticals, where they supply active pharmaceutical ingredients (APIs) and excipients, and personal care, where they provide cosmetic ingredients. Additionally, IMCD offers technical support and formulation services, which further enhance customer relationships and drive sales. Significant partnerships with leading manufacturers allow IMCD to expand its product offerings and maintain a competitive edge in the market, contributing to its overall earnings.

IMCD N.V. Financial Statement Overview

Summary
IMCD N.V. demonstrates strong revenue growth and profitability. However, there are concerns about increased leverage and declining free cash flow, indicating potential liquidity challenges.
Income Statement
82
Very Positive
The company has demonstrated steady revenue growth with a 6.4% increase from 2023 to 2024. Gross profit margin is strong at 25.4%, and the net profit margin is relatively healthy at 5.9%. However, there is a slight decline in EBIT margin from 9.6% in 2023 to 9.0% in 2024, indicating a potential area for operational improvement.
Balance Sheet
76
Positive
The debt-to-equity ratio has increased to 0.78, reflecting higher leverage, which could pose risks if not managed carefully. However, the company maintains a strong equity ratio of 45.4%, indicating a solid capital structure. Return on equity remains robust at 12.6%, reflecting effective use of shareholder funds.
Cash Flow
70
Positive
There is a significant decrease in free cash flow from 2023 to 2024, with a free cash flow growth rate of -33.9%. The operating cash flow to net income ratio is 1.0, indicating decent cash generation relative to net income. The decline in free cash flow suggests potential challenges in maintaining liquidity.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.73B4.44B4.60B3.44B2.77B
Gross Profit1.20B1.12B1.15B836.32M647.48M
EBITDA589.14M566.90M574.63M394.79M258.23M
Net Income278.24M292.27M313.08M207.28M120.13M
Balance Sheet
Total Assets4.88B4.15B3.64B3.27B2.71B
Cash, Cash Equivalents and Short-Term Investments522.78M394.46M222.00M177.88M169.01M
Total Debt1.73B1.28B722.60M409.63M691.22M
Total Liabilities2.66B2.43B1.97B1.81B1.45B
Stockholders Equity2.21B1.72B1.67B1.46B1.26B
Cash Flow
Free Cash Flow252.76M382.54M277.58M177.55M220.04M
Operating Cash Flow279.21M420.01M298.84M196.26M242.37M
Investing Cash Flow-387.95M-394.59M-255.36M-196.13M-394.30M
Financing Cash Flow247.06M216.97M-20.00K4.73M240.37M

IMCD N.V. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price95.30
Price Trends
50DMA
105.39
Negative
100DMA
112.05
Negative
200DMA
125.01
Negative
Market Momentum
MACD
-3.22
Negative
RSI
40.07
Neutral
STOCH
79.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:IMCD, the sentiment is Negative. The current price of 95.3 is above the 20-day moving average (MA) of 94.79, below the 50-day MA of 105.39, and below the 200-day MA of 125.01, indicating a neutral trend. The MACD of -3.22 indicates Negative momentum. The RSI at 40.07 is Neutral, neither overbought nor oversold. The STOCH value of 79.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NL:IMCD.

IMCD N.V. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
€5.58B20.7114.32%2.27%6.09%-7.18%
57
Neutral
$1.84B9.348.02%2.47%5.38%-37.86%
€10.27B25.079.60%
€117.39M-37.84%
€1.01B15.058.84%
€1.05B59.30
€2.93B8.5912.63%
* Services Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NL:IMCD
IMCD N.V.
95.30
-46.84
-32.95%
GB:0A00
Akzo Nobel NV
59.30
4.66
8.53%
GB:0RNP
Avantium N.V.
13.25
-9.05
-40.58%
GB:0QHL
Corbion NV
17.30
-3.48
-16.75%
GB:0QGH
OCI N.V.
4.97
0.52
11.69%
GB:0RHI
Signify NV
22.78
2.70
13.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 31, 2025